These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8551 related articles for article (PubMed ID: 16485879)

  • 1. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
    Scheinfeld N
    J Drugs Dermatol; 2006 Feb; 5(2):117-22. PubMed ID: 16485879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Imatinib and solid tumours].
    Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
    Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New oncological treatment principle with imatinib].
    Kuenen BC; Pinedo HM
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Imatinib--a new perspective in the treatment of tumors].
    Klener P; Klamová H
    Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.
    Breccia M; Alimena G
    Leuk Res; 2009 Jul; 33(7):871-5. PubMed ID: 19307018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib: new indication. New indications, but not robust evidence.
    Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
    Koon HB; Bubley GJ; Pantanowitz L; Masiello D; Smith B; Crosby K; Proper J; Weeden W; Miller TE; Chatis P; Egorin MJ; Tahan SR; Dezube BJ
    J Clin Oncol; 2005 Feb; 23(5):982-9. PubMed ID: 15572730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
    Cortes J; Kantarjian H
    Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate causes hypopigmentation in the skin.
    Tsao AS; Kantarjian H; Cortes J; O'Brien S; Talpaz M
    Cancer; 2003 Dec; 98(11):2483-7. PubMed ID: 14635084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical studies with imatinib in 2004].
    Eckhardt S
    Orv Hetil; 2005 May; 146(18 Suppl 1):941-4. PubMed ID: 15921309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months.
    Michael M; Antoniades M; Lemesiou E; Papaminas N; Melanthiou F
    Oncologist; 2009 Dec; 14(12):1198-200. PubMed ID: 19955186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pigmentary changes in a patient treated with imatinib.
    Balagula Y; Pulitzer MP; Maki RG; Myskowski PL
    J Drugs Dermatol; 2011 Sep; 10(9):1062-6. PubMed ID: 22052279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
    McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
    Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Imatinib].
    Urabe A
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1191-6. PubMed ID: 12938280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Targeted therapy of dermatofibrosarcoma with imatinib].
    Ugurel S
    J Dtsch Dermatol Ges; 2007 Mar; 5(3):261. PubMed ID: 17338806
    [No Abstract]   [Full Text] [Related]  

  • 20. [An advance in the treatment of CML].
    Ohnishi K
    Gan To Kagaku Ryoho; 2007 Dec; 34(13):2185-90. PubMed ID: 18079618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 428.